Silk Road Therapeutics

[Not Yet Scheduled]
Clinical stage company focused on rare diseases and 505b2 regulatory pathway. Our lead product SRT-001 ($200M annual revenue potential determined by independent third party) for Behcet's Disease showed very promising results at the Phase 2 proof-of-concept trial. The results of the trial were presented at American College of Rheumatology annual meeting on November 2019. We are excited to meet with FDA for future discussion on moving the program forward.

On January 2020, we've received a "May Proceed" letter from FDA on our SRT-002 drug product for Phase 2 proof-of-concept trial in US.

As we have proved the concept on the effectiveness of SRT-001, we are now looking for partners and fundraising for the next phase of drug development.
Company Type:
Privately Funded Company
Company Website:
Company HQ State:
District Of Columbia  
Company HQ Country:
United States
Year Founded:
2018
Main Therapeutic Focus:
Lead Product in Development:
SRT-001
Development Phase of Primary Product:
Number Of Unlicensed Products (For Which You Are Seeking Partners):
2
Speaker
photo
Chief Executive Officer
Silk Road Therapeutics